Oseni Side Effects

Generic Name: alogliptin / pioglitazone

Note: This document contains side effect information about alogliptin / pioglitazone. Some of the dosage forms listed on this page may not apply to the brand name Oseni.

Some side effects of Oseni may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to alogliptin / pioglitazone: oral tablet

Along with its needed effects, alogliptin / pioglitazone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking alogliptin / pioglitazone:

More common
  • Anxiety
  • blurred vision
  • chest pain
  • chills
  • cold sweats
  • coma
  • confusion
  • cool, pale skin
  • decreased urine output
  • depression
  • dilated neck veins
  • dizziness
  • extreme fatigue
  • fast heartbeat
  • headache
  • increased hunger
  • irregular breathing
  • irregular heartbeat
  • nausea
  • nightmares
  • seizures
  • shakiness
  • slurred speech
  • swelling of the face, fingers, feet, or lower legs
  • tightness in the chest
  • troubled breathing
  • unusual tiredness or weakness
  • weight gain
Rare
  • Blistering, peeling, or loosening of the skin
  • bloating
  • blood in the urine
  • constipation
  • cough
  • darkened urine
  • diarrhea
  • difficulty with swallowing
  • feeling of discomfort
  • fever
  • frequent, strong, or increased urge to urinate
  • hives
  • indigestion
  • inflammation of the joints
  • itching
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • muscle aches
  • pain in the back, lower abdomen, or stomach
  • painful urination
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rash
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • swollen lymph glands
  • vomiting
  • yellow eyes or skin
Incidence not known
  • Change in vision
  • general feeling of tiredness or weakness
  • light-colored stools
  • stomach pain, continuing

Some side effects of alogliptin / pioglitazone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common
  • Back pain
  • body aches or pain
  • ear congestion
  • loss of voice
  • sneezing
  • stuffy or runny nose

For Healthcare Professionals

Applies to alogliptin / pioglitazone: oral tablet

General

The most common side effect reported include nasopharyngitis, back pain and upper respiratory tract infection.

Cardiovascular

Alogliptin:
Common (1% to 10%): Hypertension (2.3%)

Pioglitazone:
Common (1% to 10%): Congestive heart failure (CHF) (8.2%), at least one hospitalized CHF event (5.7%), hospitalization for worsening CHF (4.7%), non-fatal, hospitalized CHF (4.7%), death due to cardiovascular causes (2.3%), emergency room visit for CHF (1.2%), fatal CHF (1%)
Postmarketing reports: Congestive heart failure (with and without known heart disease and with and without concomitant insulin)

Endocrine

Alogliptin-Pioglitazone:
Common (1% to 10%): Hypoglycemia (up to 4.5%)

Alogliptin:
Common (1% to 10%): Hypoglycemia (up to 5.4%)

Pioglitazone:
Common (1% to 10%): Hypoglycemia (up to 4.7%)

Gastrointestinal

Alogliptin:
Uncommon (0.1% to 1%): Pancreatitis (0.2%)
Postmarketing reports: Acute pancreatitis

Hematologic

Pioglitazone:
Uncommon (0.1% to 1%): Elevated ALT (0.3%)
Frequency not reported: Decreased hemoglobin and hematocrit

Hepatic

Alogliptin:
Postmarketing reports: Hepatic enzyme elevations, fulminant hepatic failure

Pioglitazone:
Uncommon (0.1% to 1%): Elevated serum alanine aminotransferase (ALT) (0.3%)
Postmarketing reports: Fatal and non-fatal hepatic fail

Hypersensitivity

Alogliptin:
Uncommon (0.1% to 1%): Hypersensitivity reactions (0.6%)
Postmarketing reports: Anaphylaxis, angioedema, rash, urticaria, severe cutaneous adverse reactions (Stevens-Johnson syndrome)

Metabolic

Pioglitazone:
Frequency not reported: Weight gain, edema
Postmarketing reports: Rapid increased in weight

Musculoskeletal

Alogliptin-Pioglitazone:
Common (1% to 10%): Back pain (4.2%)

Alogliptin:
Common (1% to 10%): Back pain (2%)

Pioglitazone:
Common (1% to 10%): Myalgia (5.4%), back pain (3.4%)
Uncommon (0.1% to 1%): Elevation in serum creatine phosphokinase (CPK) (0.2%)

Nervous system

Alogliptin:
Common (1% to 10%): Headache (4.2%)

Pioglitazone:
Common (1% to 10%): Headache (9.1%)

Ocular

Pioglitazone:
Postmarketing reports: Macular edema

Oncologic

Pioglitazone:
Uncommon (0.1% to 1%): Bladder cancer (up to 0.44%)

Respiratory

Alogliptin-Pioglitazone:
Very common (10% or more): Nasopharyngitis (4.9%), upper respiratory tract infection (4.1%)

Alogliptin:
Common (1% to 10%): Influenza (5.5%), nasopharyngitis (4.7%), upper respiratory tract infection (4.3%)

Pioglitazone:
Common (1% to 10%): Upper respiratory tract infection (up to 13.2%), sinusitis (6.3%), nasopharyngitis (3.9%)

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)